Lifetime influences on imaging markers of adverse brain health and vascular disease.

Cereb Circ Cogn Behav

Centre for Clinical Brain Sciences, University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK.

Published: December 2023

Cerebral small vessel disease (cSVD) is highly prevalent in the general population, increases with age and vascular risk factor exposure, and is a common cause of stroke and dementia. There is great variation in cSVD burden experienced in older age, and maintaining brain health across the life course requires looking beyond an individual's current clinical status and traditional vascular risk factors. Of particular importance are social determinants of health which can be more important than healthcare or lifestyle choices in influencing later life health outcomes, including brain health. In this paper we discuss the social determinants of cerebrovascular disease, focusing on the impact of socioeconomic status on markers of cSVD. We outline the potential mechanisms behind these associations, including early life exposures, health behaviours and brain reserve and maintenance, and we highlight the importance of public health interventions to address the key determinants and risk factors for cSVD from early life stages.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10827485PMC
http://dx.doi.org/10.1016/j.cccb.2023.100194DOI Listing

Publication Analysis

Top Keywords

brain health
12
vascular risk
8
risk factors
8
social determinants
8
early life
8
health
7
lifetime influences
4
influences imaging
4
imaging markers
4
markers adverse
4

Similar Publications

Article Synopsis
  • A study evaluated the impacts of divalproex sodium on brain volumes in patients with mild to moderate Alzheimer’s disease using MRI scans over 24 months.
  • The results indicated that participants receiving divalproex experienced a significantly higher decline in hippocampal and brain volumes compared to those on placebo, along with a faster decline in cognitive function as measured by the Mini-Mental State Examination.
  • The findings suggest that divalproex treatment is linked to accelerated brain volume loss and potentially increased cognitive impairment, although the long-term effects remain unclear.
View Article and Find Full Text PDF
Article Synopsis
  • The study tested whether divalproex sodium (valproate) could prevent or delay agitation and psychosis in individuals with moderate Alzheimer's disease, enrolling 313 participants.
  • After two years of treatment, results showed no significant difference between the valproate and placebo groups regarding the time to development of agitation or psychosis.
  • Additionally, the valproate group experienced more side effects and showed greater reductions in brain volume, indicating potential adverse effects of the treatment.
View Article and Find Full Text PDF

Objective: To delineate the trajectories of Aβ42 level in cerebrospinal fluid (CSF), fludeoxyglucose F18 (FDG) uptake using positron emission tomography, and hippocampal volume using magnetic resonance imaging and their relative associations with cognitive change at different stages in aging and Alzheimer disease (AD).

Design: Cohort study.

Setting: The 59 study sites for the Alzheimer's Disease Neuroimaging Initiative.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!